

Identifying profiles, trajectories, burden, social and biological factors in 3.3 million individuals with multimorbidity in England

Yu Liu^{1,†}, Clare Bankhead², Cynthia Wright Drakesmith², Catherine Pope², David Gonzalez-Chica³, Subhashisa Swain², CoMPuTE*, Carl Heneghan², Rafael Perera-Salazar², and Tingting Zhu¹

¹Department of Engineering Science, University of Oxford, Oxford, UK

²Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK

³Discipline of General Practice, University of Adelaide, Adelaide, Australia

*A list of authors and their affiliations appears at the end of the paper

†Corresponding author: yu.liu@eng.ox.ac.uk

1 **Multimorbidity, the co-occurrence of multiple chronic conditions in an individual, has be-**
2 **come a global health challenge affecting populations in high-income and low- to middle-**
3 **income countries. Despite its increasing prevalence, critical gaps remain in understand-**
4 **ing its progression, burden, and determinants to better guide prevention and treatment.**
5 **Here, by leveraging linked primary care, hospitalisation, and mortality records from 3.3**
6 **million individuals with multimorbidity in England, we conducted a longitudinal cohort**
7 **study to characterise multimorbidity across multiple dimensions, including condition pro-**
8 **filing, progression trajectories, healthcare burden, and associated social and biological**
9 **factors. Specifically, we identified 21 distinct multimorbidity profiles in males and 18 in**
10 **females, uncovering life-course progression pathways. We assessed the differential bur-**
11 **den of these profiles on mortality and hospitalisation. The study also highlights how social**
12 **inequalities shape distinct patterns of multimorbidity. Furthermore, by developing an in-**
13 **terpretable machine learning framework, we identified key biological markers associated**
14 **with specific multimorbidity profiles. Together, these results offer valuable insights to in-**
15 **form prevention strategies, public health initiatives and potential interventions aimed at**
16 **mitigating the growing burden of multimorbidity.**

17 Introduction

18 Multimorbidity, the co-occurrence of two or more chronic conditions in an individual, threat-
19 ens individual health and overwhelms healthcare systems^{1,2}. Globally, more than one-third of
20 adults are affected^{3,4}, and in England alone, annual healthcare costs per patient increase from
21 £3,000 for those with a single condition to £8,000 for those with three or more conditions⁵. De-
22 spite the growing burden, most clinical guidelines remain focused on single conditions, making
23 them inadequate for people with multiple mental and physical health conditions, who are gener-
24 ally associated with poorer quality of life, shorter life expectancy, greater functional difficulties,
25 and increased use of healthcare¹. In addition, the complexity of multimorbidity extends beyond
26 the simple accumulation of conditions, as its mechanisms vary quantitatively and qualitatively
27 across sexes, stages of life, and a spectrum of social and biological factors^{1,6–10}, highlighting
28 the urgent need to better understand multimorbidity to enable more effective prevention, earlier
29 detection, and improved clinical management.

30 As the accumulation of conditions is a well-recognised characteristic of multimorbid-
31 ity, several studies have measured it by counting the number of conditions per individual^{11–13}.
32 However, these studies lack information on the composition and interplay of conditions within
33 multimorbidity. Motivated by the observation that individuals with common conditions tend
34 to cluster in clinical practice and epidemiological studies¹⁴, various methods have been used
35 to identify multimorbidity profiles in cross-sectional studies^{15,16}, with latent class analysis
36 (LCA)¹⁷ emerging as the most widely used approach^{7,18}. Several clinically meaningful profiles
37 have been identified, such as cardiovascular and cardiometabolic profiles^{19,20}. Although these
38 studies have improved our understanding of generic patterns in multimorbidity, their cross-
39 sectional design fails to capture the longitudinal progression.

40 Taking advantage of the digitalisation of healthcare systems and the accumulation of sub-
41 stantial longitudinal data from electronic health records (EHRs), some studies have investigated
42 multimorbidity trajectories^{21–24}. Evidence indicates substantial transitions from profiles char-
43 acterised by cardiovascular risk factors such as diabetes and hypertension, to those dominated
44 by explicit cardiovascular conditions such as heart attack and stroke, reflecting the dynamic na-
45 ture of multimorbidity²⁵. However, most studies followed individuals for less than 15 years²⁶.
46 Such time frames capture only partial life stages, such as early adulthood (e.g., 25–45 years),
47 middle adulthood (e.g., 45–65 years) or late adulthood (e.g., 65–85 years)²⁷. Therefore, lon-
48 gitudinal studies that span the full life course are essential to fully characterise multimorbidity
49 trajectories, and understand their cumulative burden on individual quality of life over time.

50 In parallel, the role of social and biological factors in shaping multimorbidity has been

51 increasingly recognised^{1,6–8}. Socioeconomic inequalities, for example, have been shown to
52 significantly influence multimorbidity, with disadvantaged groups experiencing earlier onset
53 and faster accumulation of chronic conditions^{28–30}. Despite these insights, the specific contri-
54 butions of social factors to the emergence and persistence of different multimorbidity profiles
55 remain poorly understood²⁰. From a biological perspective, while clinical markers such as high
56 body mass index (BMI) have been linked to multimorbidity development³¹, few studies have
57 systematically examined multiple routinely collected clinical measures^{10,32}, hindering a deeper
58 understanding of the underlying biological factors.

59 Taken together, despite growing recognition of multimorbidity's complexity, no study has
60 systematically characterised its composition, progression, and impact, alongside underlying
61 social and biological factors, within a large population-based cohort to inform more effective
62 preventive strategies and targeted interventions^{8,33}. Motivated by this gap, we examined key
63 aspects of multimorbidity throughout the life course of 3.3 million individuals in England using
64 the Clinical Practice Research Datalink (CPRD) data³⁴, a representative sample of the English
65 primary care population^{35,36}. The study was structured around five objectives: (1) We identified
66 multimorbidity profiles using LCA and hierarchical clustering, stratified by age and sex; (2) We
67 characterised life-course multimorbidity trajectories throughout the study population; (3) We
68 assessed the burden of multimorbidity in terms of both mortality and hospitalisation; (4) We
69 analysed the association between multimorbidity and social factors, including socioeconomic
70 deprivation, ethnicity and geography; (5) We investigated the biological factors underlying
71 multimorbidity, developing an interpretable machine learning framework to identify clinically
72 relevant markers for specific multimorbidity profiles.

73 **Results**

74 **Data overview and study design**

75 Using routinely collected EHR data from CPRD³⁴, we derived the longitudinal diagnoses of
76 18 chronic conditions in 6,671,245 individuals. These conditions represent the commonly re-
77 ported chronic conditions in the general population^{37–40}, across mental, respiratory, metabolic,
78 cardiovascular, neurological, and other systems (Methods). Individuals entered the study at
79 birth and were followed until death or study exit, with follow-up period ended no later than
80 31 December 2019. Among the study cohort, 3,314,652 individuals developed multimorbidity
81 (i.e. two or more of the investigated chronic conditions) at the time of death or exit, with an
82 overall prevalence of 49.69% (95% confidence interval [CI]: 49.65–49.72%). These individu-
83 als made up the primary study cohort, with a median duration of 68 years (interquartile range

84 [IQR]: 50–81 years) from birth to death or exit, and a median year of birth of 1950 (IQR: 1936–
85 1968; Supplementary Fig. S1). Table 1 summarises the basic characteristics of this group. For
86 comparison, we identified 1,226,245 individuals from the study cohort who remained free of
87 all 18 conditions throughout the study period, referred to as the healthy cohort. The remaining
88 2,130,348 individuals developed one of the 18 conditions during the study period. For clarity,
89 we refer to some of selected conditions using abbreviations: coronary heart disease (CHD),
90 chronic obstructive pulmonary disease (COPD), and serious mental illnesses (SMI).

91 The overall framework of our analysis is described in Fig. 1. To capture multimorbidity
92 progression over time, we divided each individual's clinical history into nine age bands
93 (<18, 18–24, 25–34, 35–44, 45–54, 55–64, 65–74, 75–84, ≥85) and stratified analyses by sex.
94 Within each age band, LCA¹⁷ was applied to identify clusters of individuals with similar di-
95 agnostic profiles (Fig. 1a). To identify generic multimorbidity profiles across the life course,
96 clusters from different age bands were merged using hierarchical clustering based on condi-
97 tion prevalence and exclusivity patterns (Fig. 1b and Supplementary Fig. S2–S4). Life-course
98 multimorbidity trajectories were reconstructed by linking individuals' profiles across succes-
99 sive age bands (Fig. 1c). Using 847,048 death records and 33,950,515 hospitalisation records
100 from the Office for National Statistics (ONS)⁴¹ and Hospital Episode Statistics (HES)⁴², we
101 assessed the burden of multimorbidity in terms of mortality and hospitalisation across profiles
102 and age bands (Fig. 1d). We then analysed the association between multimorbidity profiles and
103 various social factors (Fig. 1e and Supplementary Table S1). For socioeconomic deprivation,
104 individuals were linked to quintiles of the 2019 English Index of Multiple Deprivation (IMD)
105 as a measure of relative deprivation²⁸. For ethnicity, individuals were grouped by White, Black,
106 South Asian, Mixed, and Other¹². For geography, each individual was assigned to one of nine
107 regions in England. Using 1,064,737,538 records covering 45 clinical markers from CPRD,
108 we developed an interpretable machine learning framework that combines XGBoost⁴³ with a
109 novel reference-adjusted Shapley additive explanation (SHAP) method^{44,45} to identify clin-
110 ically meaningful markers associated with each multimorbidity profile (Fig. 1f and Methods).
111 The complete marker list appears in Supplementary Table S2.

112 **Multimorbidity profiles**

113 Throughout the life course, 21 multimorbidity profiles for males and 18 for females were iden-
114 tified in the primary study cohort (Fig. 2). Detailed numerical results are provided in Sup-
115 plementary Fig. S5 and Table S3–S4, and the naming convention for profiles is provided in
116 Supplementary Note S1.2.

117 The multimorbidity profiles showed clear age-related trends that became increasingly
118 more prevalent and complex with ageing, in terms of both composition and accumulation of
119 conditions. In early life (<35 years), profiles were predominantly characterised by mental
120 health conditions, often co-occurring with asthma (M1–M5 in males and F1–F6 in females).
121 In midlife (35–64 years), physical conditions such as hypertension, diabetes, and cancer be-
122 came more prominent (M6–M12, F7–F13). In later life (≥65 years), newly emerging profiles
123 reflected increased complexity and multisystem involvement, especially in the cardiovascular,
124 cardiometabolic, renal, and mental health domains (M13–M21, F14–F18).

125 Complex multimorbidity profiles, defined as those with more than four conditions on av-
126 erage⁶, were identified in older adults. In the ≥85 age band, males in M14 (Cardiovascular
127 + Cardiometabolic + Renal, Complex) and M15 (Mental + Cardiovascular + Cardiometabolic
128 + Renal + Respiratory, Complex) had average condition counts of 5.86 (SD: 1.34) and 7.03
129 (SD: 1.30), respectively, while females in F16 (Cardiovascular + Cardiometabolic + Renal,
130 Complex) and F15 (Mental + Cardiovascular + Cardiometabolic + Renal + Respiratory + Mus-
131 culoskeletal, Complex) had averages of 4.53 (SD: 1.48) and 7.02 (SD: 1.33). Mental health
132 conditions were over-represented in M15 and F15, with depression affecting more than 85% of
133 the individuals in both profiles, compared to less than 20% in M14 and F16. In contrast, M14
134 and F16, while also complex, showed a higher prevalence of heart failure and atrial fibrillation.
135 The prevalence of heart failure was 87.11% (95% CI: 86.90–87.31%) in M14 and 50.22% (95%
136 CI: 50.01–50.43%) in F16, compared to 46.04% (95% CI: 45.54–46.54%) in M15 and 33.42%
137 (95% CI: 33.08–33.76%) in F15.

138 Several multimorbidity profiles exhibited long persistence—appearing repeatedly across
139 successive age bands. The mental health-only profiles (M1 and F1: Anxiety + Depression)
140 were observed across six age bands under age 65, highlighting their widespread impact across
141 a broad population. Among profiles dominated by physical conditions, F10 (Cardiometabolic
142 + Renal) in females and M11 (CHD-predominant Cardiovascular + Diabetes) in males were
143 the most persistent, each spanning five consecutive age bands from age 45 and above.

144 Sex differences in multimorbidity patterns were evident, with males being more fre-
145 quently included in cardiovascular, respiratory, and cancer-related profiles. Six cardiovascular-
146 related profiles were identified in males (M11, M14, M15, M19–M21) compared to four in
147 females (F11, F14, F15, F18). Although both sexes had a CHD-predominant profile (M11,
148 F11), M11 was more prevalent and persisted throughout a broader age range, while F11 was
149 observed only in two age bands (45–64 years). Although asthma-predominant respiratory pro-
150 files were common in both sexes (M9, F9, F12), severe respiratory conditions such as COPD

151 were predominantly observed in males: M19 (COPD-predominant Respiratory + Cardiovas-
152 cular) showed a COPD prevalence of 81.37% (95% CI: 81.09–81.70%). Similarly, cancer
153 appeared more prominently in male profiles, with a prevalence of 51.70% (95% CI: 51.13–
154 52.27%) in M16 (Cancer + COPD + Cardiovascular) and 100% in M18 (Cancer + Physical
155 Long-term Conditions). Unlike males, females had a higher prevalence of mental, neuro-
156 logical, and musculoskeletal profiles. For example, F14 (Mental + Physical Long-term Con-
157 ditions) had a prevalence of 15.54% (95% CI: 15.46–15.62%) in ages 75–84, compared to
158 9.91% (95% CI: 9.83–9.99%) of the comparable male profile M13 (Mental + Physical Long-
159 term Conditions). Dementia-predominant neurological profiles were also more prevalent in
160 females (F18: 15.76%, 95% CI: 15.65–15.88% in ≥ 85 years) than males (M20: 8.07%, 95%
161 CI: 7.95–8.18%), and often involved musculoskeletal conditions. A female-specific profile,
162 F13 (Osteoporosis-predominant Musculoskeletal + Hypertension + Cancer), spanned four age
163 bands from age 55 and had an osteoporosis prevalence of 94.87% (95% CI: 94.76–94.97%).

164 **Multimorbidity trajectories**

165 Longitudinal transitions between multimorbidity profiles across age bands were observed (Fig. 3
166 and Supplementary Fig. S6). The Sankey diagrams illustrate that the population with multimor-
167 bidity increased with age, peaking in the 65–74 age band as individuals accumulated conditions.
168 This was followed by a decline in the older age bands due to mortality and exit from the study.
169 Several distinct progression pathways were identified.

170 In both sexes, mental health–predominant profiles often represented early multimorbidity,
171 and individuals within these profiles progressed to more complex profiles incorporating age-
172 related physical conditions. The mental health-only profiles (M1 and F1: Anxiety + Depres-
173 sion) frequently transitioned into profiles that added hypertension and diabetes. For example,
174 between ages 45–64, a subset of individuals from M1/F1 moved to M6/F7 (both Hypertension
175 + Depression + Anxiety). In the 65–74 age band, M13 and F14 (both Mental + Physical Long-
176 term Conditions) emerged, with 41.29% of males and 57.93% of females originating from M1
177 and F1, an additional 35.62% of males and 29.37% of females from M6 and F7, and the remain-
178 ing individuals contributed from M8 (Mental + Diabetes + Cancer) and F8 (Mental + Cancer +
179 Diabetes), respectively.

180 For cardiovascular-predominant trajectories, direct transitions from healthy or single-
181 condition states into M11 (CHD-predominant Cardiovascular + Diabetes) were common. 72.32%
182 and 64.68% of individuals entered M11 from these groups in the 45–54 and 55–64 age bands,
183 respectively. Subsequently, M11 served as a key precursor to more complex profiles such as

184 M14 (Cardiovascular + Cardiometabolic + Renal, Complex), contributing 42.25% and 31.22%
185 of its population in the 65–74 and 75–84 age bands, respectively. A similar pattern was ob-
186 served in females, with transitions from F11 (CHD-predominant Cardiovascular + Diabetes +
187 Mental) to F16 (Cardiovascular + Cardiometabolic + Renal, Complex).

188 For cardiometabolic- and renal-predominant trajectories, notable sex-specific patterns
189 were observed. In males, a considerable proportion of individuals transitioned from healthy
190 or single-condition states to M10 (Hypertension + Diabetes), which persisted across three age
191 bands (45–74 years), and M12 (Hypertension + Cancer + Renal), present at ages 55–74. These
192 two profiles served as key intermediates in the development of M17 (Cardiometabolic + Renal)
193 in the 75–84 age band, together accounting for 70.95% of its population. They also preceded
194 M18 (Cancer + Physical Long-term Conditions), contributing 79.70% of its population. In
195 females, a similar pathway was observed involving F10 (Cardiometabolic + Renal) and F17
196 (Hypertension + Cancer + Renal), both of which included a substantial number of individuals
197 transitioning from healthy or single-condition states, and 45.50% of individuals transitioned
198 from F17 to F10 in the 75–84 age band. Both contributed to the formation of F16 (Cardiovas-
199 cular + Cardiometabolic + Renal, Complex).

200 Distinct sex differences were evident in respiratory-predominant trajectories. In males,
201 M9 (Asthma-predominant Respiratory + Hypertension), observed across four age bands (35–74
202 years), often served as a precursor to M19 (COPD-predominant Respiratory + Cardiovascular)
203 in the 75–84 age band, with 43.53% of individuals making this transition. In females, respira-
204 tory progression was more closely intertwined with mental health conditions. F5 (Depression
205 + Asthma), present at ages 18–34, transitioned almost entirely (96.14%) into F2 (Asthma +
206 Depression + Anxiety) in the 35–44 age band due to the accumulation of mental health condi-
207 tions. Between ages 45–64, F2 contributed over 45% of individuals to F9 (Asthma-predominant
208 Respiratory + Mental). Subsequently, 41.71% of the individuals in F9 transitioned to F12
209 (Asthma-predominant Respiratory + Hypertension), in which hypertension was highly preva-
210 lent (65.31%, 95% CI: 65.12–65.51%).

211 In addition, we examined the number of unique multimorbidity profiles each individual
212 experienced (Supplementary Fig. S7). Among the 3.3 million individuals in the primary study
213 cohort, 58.53% of males and 58.43% of females stayed in a single profile across all age bands,
214 while 35.40% of males and 34.74% of females experienced two distinct profiles. The remaining
215 6.07% of males and 6.83% of females transitioned through three or more profiles. On average,
216 males experienced 1.48 (SD: 0.62) profiles, and females experienced 1.49 (SD: 0.64) profiles
217 during the study period.

218 Burden of multimorbidity

219 The burden associated with multimorbidity was assessed using three indicators: mortality
220 (Fig. 4a,b), hospitalisation rate (mean annual hospitalisations per individual; Fig. 4c,d), and
221 hospitalisation prevalence (proportion of individuals experiencing at least one hospitalisation;
222 Supplementary Fig. S8), stratified by multimorbidity profile, sex, and age. Results from the
223 healthy cohort were included as a reference. Across all indicators, the burden of multimorbidity
224 increased progressively with age. Profiles dominated by physical conditions were generally
225 associated with greater burden than those primarily driven by mental health conditions, with
226 complex multimorbidity profiles imposing the highest burden overall.

227 Mortality remained low across profiles before age 65, as compared to the levels observed
228 in the healthy cohort. Notable exceptions were M8 (Mental + Diabetes + Cancer) and F8 (Men-
229 tal + Cancer + Diabetes), with mortality respectively reaching 9.36% (95% CI: 9.15–9.57%)
230 and 6.85% (95% CI: 6.64–7.06%) in the 55–64 age band. After age 65, mortality rose sharply,
231 and stratified into three tiers in the ≥ 85 age band. The highest mortality ($\sim 70\%$) was observed
232 in neurological-predominant profiles (M20: Dementia-predominant Neurological + Cardio-
233 vascular, F18: Dementia-predominant Neurological + Cardiovascular + Musculoskeletal) and
234 complex profiles (M14 and F16: Cardiovascular + Cardiometabolic + Renal, Complex). In
235 contrast, mortality was lower ($\sim 55\%$) in mental health profiles among older individuals (M13
236 and F14: Mental + Physical Long-term Conditions) and cardiometabolic profiles (M17 and
237 F10: Cardiometabolic + Renal), with remaining profiles falling between 60–65%. Mortality
238 in the healthy cohort in the same age band was 38.54% (95% CI: 37.50–39.60%) for males
239 and 44.95% (95% CI: 44.06–45.84%) for females. Although mortality across multimorbidity
240 profiles was similar between the sexes, this gap relative to the healthy cohort suggests a
241 disproportionate mortality burden on older males.

242 Interestingly, although M15 (Mental + Cardiovascular + Cardiometabolic + Renal + Res-
243 piratory, Complex) and F15 (Mental + Cardiovascular + Cardiometabolic + Renal + Respi-
244 ratory + Musculoskeletal, Complex) had the highest average number of conditions (7.03 and
245 7.02, respectively), their mortality was lower than M14 and F16, which had fewer conditions on
246 average (5.86 and 4.53, respectively) but were heavily burdened by cardiovascular conditions
247 such as heart failure and atrial fibrillation. For example, in the ≥ 85 age band, mortality was
248 65.75% (95% CI: 64.60–66.88%) in M15, versus 69.60% (95% CI: 68.96–70.23%) in M14.

249 Hospitalisation rates followed a similar age-related trend as mortality, but varied by sex
250 and profile. In the 18–24 age band, profiles involving hypertension, cancer, and SMI (M4,
251 M5, F5, F6) were associated with elevated hospitalisation rates. Females exhibited higher hos-

252 hospitalisation rates between ages 25–44 due to pregnancy-related care, whereas males showed
253 consistently higher rates in older age bands. Between ages 45–64, cardiovascular-predominant
254 profiles imposed a higher burden on females. For example, F11 (CHD-predominant Cardiovas-
255 cular + Diabetes + Mental) had a hospitalisation rate of 0.85 (95% CI: 0.78–0.92) in the 45–54
256 age band, substantially higher than its male counterpart M11 (0.50, 95% CI: 0.47–0.53). In later
257 life, unlike mortality trends, the complex profiles M15 and F15 exhibited the highest hospitali-
258 sation rates. M15 and F15 peaked at 1.57 (95% CI: 1.48–1.67) and 1.25 (95% CI: 1.21–1.30),
259 respectively, in the 75–84 age band, while M14 and F16 showed lower rates of 1.31 (95%
260 CI: 1.26–1.35) and 0.92 (95% CI: 0.89–0.94), respectively. Notably, neurological-predominant
261 profiles (M20, F18) exhibited relatively low hospitalisation rates despite high mortality. Sim-
262 ilar trends were observed for hospitalisation prevalence (Supplementary Fig. S8), supporting
263 the consistency of the results across different healthcare burden indicators.

264 **Social factors with multimorbidity**

265 We also examined the multimorbidity profiles in relation to socioeconomic deprivation, ethnic-
266 ity, and geographic region in England (Fig. 5).

267 Socioeconomic deprivation, as measured by quintiles of the IMD, was associated with
268 distinct prevalence patterns across profiles (Fig. 5a,b). Profiles that largely occurred before age
269 65 (M1–M8, F1–F9, F11) were significantly more prevalent in the most deprived quintile (IMD
270 5) compared to the least deprived (IMD 1). In contrast, profiles that arose or peaked later in life
271 (M11–M14, M17–M21, F12–F14, F16–F18) were more common among the least deprived.

272 Pronounced ethnic differences in profile prevalence were also observed (Fig. 5c,d). Among
273 White individuals, mental health-predominant profiles were consistently more prevalent than
274 in other ethnic groups, particularly M1 and F1 (both Anxiety + Depression), and M13 and F14
275 (both Mental + Physical Long-term Conditions), with prevalence exceeding that of other groups
276 by more than 5%. COPD-related profiles, including M19 (COPD-predominant Respiratory +
277 Cardiovascular) and M16 (Cancer + COPD + Cardiovascular) were also more prevalent among
278 White males. In females, F17 (Hypertension + Cancer + Renal) had a prevalence of 14.58%
279 (95% CI: 14.52–14.64%) among White individuals, more than 5% higher than in other eth-
280 nic groups. In comparison, profiles characterised by physical conditions were more prevalent
281 among Black and South Asian populations than in White individuals. Among Black individ-
282 uals, cardiometabolic profiles such as M10 (Hypertension + Diabetes) and M7 (Hypertension
283 + Diabetes + Mental), along with M17 and F10 (both Cardiometabolic + Renal) showed the
284 highest prevalence, followed by South Asian individuals, with a considerably lower prevalence

285 in White individuals. Among South Asian individuals, profiles characterised by CHD (M11,
286 F11) and those combining asthma and hypertension (M5, M9, F9, F12) were more prevalent
287 than in other ethnic groups. Notably, South Asian males had the highest prevalence of M11 at
288 24.11% (95% CI: 23.75–24.48%), exceeding all other groups by more than 5%.

289 Several regional trends were evident (Fig. 5e,f). London was the most ethnically diverse
290 region, with more than 45% of residents identified as non-White, including 14.5% South Asian
291 and 13.5% Black individuals⁴⁶. It had the highest prevalence of profiles (M4, M5, M7, M10,
292 F4, F6, F10) commonly observed in Black and South Asian populations (Fig. 5c,d), reflect-
293 ing an overlap between ethnic and regional distributions. M10 and F10, the most prevalent
294 profiles among Black and South Asian individuals, showed the highest regional prevalence in
295 the West Midlands, the second most ethnically diverse region in England (11.3% Asian and
296 4.5% Black)⁴⁶. The regional variation in socioeconomic deprivation was also reflected in the
297 profile distributions. Except for London mainly driven by ethnic diversity, the profiles most
298 prevalent in the least deprived regions of the East of England and the South East (M9, M12,
299 M18–M21, F12, F17, F18) were also the most common in the least deprived IMD quintile
300 (IMD 1; Fig. 5a,b). In contrast, in the North East, the most deprived region in England⁴⁷, seven
301 of the 10 profiles with the highest regional prevalence mirrored those most prevalent in the most
302 deprived IMD quintile (IMD 5).

303 **Biological factors with multimorbidity**

304 We next examined the multimorbidity profiles in association with 45 routinely measured clin-
305 ical markers (Fig. 6). Relevance was defined as the extent to which abnormal marker values
306 (elevated or reduced) contributed to the correct classification of each profile (Methods).

307 Across nearly all profiles, elevated BMI and systolic blood pressure (SBP) showed high
308 relevance. In contrast, diastolic blood pressure (DBP) followed an age-dependent pattern: ele-
309 vated DBP characterised profiles occurring under age 65, whereas reduced DBP predominated
310 in cardiovascular profiles among those aged 65 years and older.

311 Respiratory-related profiles (M2, M3, M5, M9, M15, M16, M19, F2–F5, F9, F12, F15)
312 were distinguished by reduced peak expiratory flow percentage (PEF %) (Fig. S9a). Neuro-
313 logical profiles (M20, F18) exhibited the strongest relevance for reduced albumin, and F18
314 also showed a strong relevance for reduced BMI (Fig. S9b). Cancer-related profiles (M5,
315 M8, M12, M16, M18, F8, F13, F17) were associated with elevated inflammatory markers
316 including erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and plasma viscos-
317 ity (Fig. S9c). The musculoskeletal profile F13 was marked by elevated calcium and reduced

318 vitamin D. Early-life mental health profiles were associated with reduced urea and elevated
319 hepatic markers including alanine aminotransferase (ALT), total protein and albumin. Within
320 the cardiometabolic-related profiles, those with high diabetes prevalence (M7, M8, M10, M11,
321 M14, M15, M17, F8, F10, F11, F15, F16) demonstrated strong associations with markers
322 of glucose metabolism, particularly HbA1c and fasting glucose (Fig. S10a). Cardiovascular
323 profiles characterised by heart-failure prevalence (M14, M21, F16) showed relevance for ele-
324 vated bilirubin. Renal-related profiles (M12, M14, M15, M17, F10, F15–F17) were defined by
325 markers of renal dysfunction, including reduced estimated glomerular filtration rate (eGFR),
326 along with elevated urea and reduced sodium. Finally, the four complex profiles (M14, M15,
327 F15, F16) demonstrated multisystem involvement through associations with diverse markers,
328 including eGFR, PEF%, HbA1c and fasting glucose.

329 Discussion

330 Multimorbidity presents a critical challenge to both individual health and healthcare systems. In
331 this large, population-based longitudinal study of 3.3 million individuals in England, we present
332 the most comprehensive characterisation of multimorbidity to date. Using EHRs that span the
333 life course, this study is, to our knowledge, the first to identify distinct multimorbidity profiles,
334 their life-course trajectories, associated health burdens, and underlying social and biological
335 factors at a national level. Our findings reveal clinically plausible profiles that evolve with
336 age, assess the differential burden of multimorbidity on mortality and hospitalisation, highlight
337 inequalities shaped by social factors, and suggest patterns in clinical markers associated with
338 specific profiles. This new way of characterising multimorbidity can provide valuable insights
339 for clinical practice and public health policy.

340 Several findings stand out. First, our analysis reveals the long persistence of specific
341 multimorbidity profiles throughout the life course, particularly the mental health-only profile
342 during early and middle adulthood, and cardiometabolic and cardiovascular profiles emerging
343 in middle adulthood and persisting into older age. These patterns highlight the long-lasting bur-
344 den of mental health conditions and the cumulative impact of metabolic and vascular diseases.

345 Clear sex-specific patterns were also evident in our study. Males were more frequently
346 represented in cardiovascular, respiratory, and cancer-related profiles, while females were more
347 commonly represented in mental, neurological, and musculoskeletal profiles. These differences
348 reflect a combination of behavioural and biological factors: higher rates of smoking and alcohol
349 consumption among males may contribute to COPD and cancer risk, while oestrogen confers
350 cardiovascular protection for females until menopause. Differences in stress exposure, help-

351 seeking and health service variation may also play a role. For example, females are more likely
352 to seek care for depression and present with symptoms that align more closely with clinical
353 diagnostic criteria, while males with comparable scores on standardised mental health assess-
354 ments are less frequently diagnosed. Our findings highlight the need for prevention strategies
355 tailored to sex-specific risks, including reducing cardiovascular risk in males and improving
356 mental health support for females.

357 In addition, our study makes an important novel contribution to the literature by mapping
358 multimorbidity trajectories to show how different progression pathways evolve throughout the
359 life course. For example, we identified transitions from a healthy state to cardiometabolic con-
360 ditions (e.g., hypertension and diabetes) and subsequently to profiles combining cardiometabolic
361 and renal disorders. We also observed transitions from asthma-predominant profiles to COPD-
362 predominant profiles, likely driven by chronic inflammation of the airways and environmental
363 exposures such as smoking and air pollution. Similarly, progression from cardiometabolic-
364 predominant profiles to more complex profiles incorporating cardiovascular conditions may
365 reflect cumulative endothelial dysfunction, atherosclerotic burden, and lifestyle factors such as
366 physical inactivity. These life-course pathways expand previous longitudinal observations, and
367 reveal clearly defined critical transition points and age windows, which could serve as valuable
368 opportunities for preventive interventions.

369 Interestingly, approximately half of individuals with multimorbidity remained within a
370 single profile over the life course, while the remainder transitioned between multiple dis-
371 tinct profiles. These observations suggest that tailored preventive strategies may be needed:
372 those with stable multimorbidity may benefit from targeted management of specific conditions,
373 whereas those following dynamic trajectories may require broader strategies to interrupt pro-
374 gression to more complex multimorbidity.

375 Our findings also shed light on how specific conditions shape the burden of multimor-
376 bidity. Profiles exhibiting high-risk physical conditions, particularly cardiovascular and renal
377 conditions, were associated with the highest mortality, in line with previous studies^{18,48}. In
378 contrast, highly complex profiles encompassing multiple systems associated with elevated hos-
379 pitalisation rates, despite relatively lower mortality, reflect the resource-intensive demands of
380 complex multimorbidity management. Neurological profiles exhibited particularly high mor-
381 tality but only moderate hospitalisation, possibly due to management in long-term care facilities
382 or community settings, limited therapeutic options, or transitions to palliative care in advanced
383 stages of the disease. These findings emphasise the importance of moving beyond simple con-
384 dition counts in the multimorbidity assessment and considering disease interactions and clinical

385 severity for outcome management and healthcare resource allocation.

386 The study further highlights pronounced disparities in multimorbidity, shaped by socio-
387 economic deprivation, ethnicity, and geography. Individuals from deprived backgrounds expe-
388 rienced earlier onset and greater burden of multimorbidity before age 65, whereas later-life
389 multimorbidity was more prevalent among less deprived groups. This probably reflects the
390 interplay of survival bias, differential access to healthcare, and the protective effects of so-
391 cieconomic advantage: deprived populations experience earlier disease onset and premature
392 mortality, whereas more affluent individuals are more likely to survive into older age, where
393 the cumulative nature of ageing leads to higher prevalence of complex multimorbidity profiles.

394 In addition to socioeconomic deprivation, ethnicity played a significant role. White pop-
395 ulations showed a higher prevalence of mental health-predominant profiles, potentially reflect-
396 ing cultural and systemic determinants in awareness, help-seeking, and diagnosis. At the same
397 time, minority ethnic populations may face reduced access to mental health services. In addi-
398 tion, White populations were more represented in cancer-related profiles, likely due to greater
399 participation in screening programmes, which in turn increases the incidence rates of certain
400 cancers. This is also associated with a higher prevalence of risk factors, such as smoking
401 and obesity, compared to other ethnic groups. In contrast, South Asian and Black populations
402 showed a higher prevalence in cardiovascular and cardiometabolic profiles, which is consis-
403 tent with differences in insulin resistance and dietary patterns, including significantly higher
404 salt and carbohydrate consumption⁴⁹. These findings confirm the role of social factors, in-
405 cluding structural healthcare inequalities, in shaping multimorbidity, highlighting the need for
406 targeted interventions, including optimised cardiometabolic management, equitable screening
407 programmes, and enhanced mental health outreach for at-risk populations.

408 Regional variations further reflected the interplay of ethnicity and socioeconomic depri-
409 vation in multimorbidity. Ethnic diversity emerged as the dominant factor in London, while
410 socioeconomic deprivation had a stronger influence in the North East. Elsewhere, the rela-
411 tionship between these factors and multimorbidity was more heterogeneous, highlighting the
412 importance of examining social factors on granular geographical scales where population char-
413 acteristics are more homogeneous. We acknowledge, however, that these disparities arise not
414 only from the investigated social factors but also from systemic biases in diagnosis, unequal
415 environmental exposures, historical mistrust of healthcare systems and other structural deter-
416 minants, necessitating interventions that address both clinical management and the broader
417 contextual forces shaping health.

418 An important novelty of our study lies in the systematic integration of clinical markers

419 with multimorbidity profiles through an interpretable machine learning framework. Several
420 observed associations, such as elevated BMI and SBP across all profiles, are consistent with
421 established roles of obesity and hypertension in multimorbidity development⁵⁰, while the asso-
422 ciations of calcium and vitamin D with the musculoskeletal profile align with known metabolic
423 imbalances underlying osteoporosis⁵¹. The consistency of these associations across a large,
424 representative population supports the external validity of the framework and highlights its
425 utility in identifying clinically relevant patterns. Importantly, this study extends beyond prior
426 studies in several key aspects. First, unlike most efforts that focus on single conditions, our
427 framework enables fine-grained, profile-specific marker association analysis across multimor-
428 bidity profiles. Second, the model is trained on a uniquely large and diverse primary care
429 dataset, providing greater power and population generalisability compared to earlier studies
430 typically based on smaller or more selective cohorts.

431 Importantly, we identified several underexplored or novel marker associations with mul-
432 timorbidity profiles. For example, the age-dependent pattern with DBP reflects the progression
433 toward isolated systolic hypertension in ageing populations, mediated by progressive arterial
434 stiffening and loss of vascular compliance⁵². The elevation of hepatic markers in mental health-
435 predominant profiles may reflect unmeasured confounding, such as alcohol use, psychotropic
436 medication effects, or systemic inflammation, and suggest biological pathways not previously
437 recognised in this context. Similarly, the prominence of albumin in neurological profiles and
438 bilirubin in heart failure profiles provides interpretable markers, plausibly linked to cognitive
439 decline and hepatic congestion, respectively. Together, these findings underscore the transla-
440 tional potential of our approach. By linking clinical markers to multimorbidity profiles, our
441 framework enables more precise risk stratification, earlier detection of individuals at elevated
442 multimorbidity risk, and the development of tailored screening and management protocols. Its
443 adaptability supports further applications across diverse populations and broader marker panels
444 to enhance diagnostic decision-making and inform therapeutic strategies.

445 Our study design should be interpreted in light of several limitations. First, we assume
446 that all 18 conditions persist after diagnosis, potentially overlooking recovery, undiagnosed
447 or unrecorded underlying conditions, and misrepresenting acute events such as stroke, which
448 have a transient onset but lasting impact. Second, the use of CPRD data introduces inherent
449 biases, particularly related to access to primary care, influenced by factors such as the inverse
450 care law, where individuals with higher needs may receive inadequate care. In addition, the
451 quality of general practitioner coding, which is heavily influenced by the Quality and Outcomes
452 Framework (QOF)⁵³, could affect the accuracy of diagnoses and clinical marker measurements,

453 although the large sample size and advanced analytical methods help mitigate these concerns.
454 Third, the design of this observational study inherently restricts causal inferences, especially
455 in analyses involving social factors and associations of clinical markers. Furthermore, while
456 we examined the influence of social factors on multimorbidity, we did not account for their
457 potential interactions or confounding effects, which may overlook the complex interplay among
458 these factors in shaping multimorbidity. Lastly, we were unable to fully adjust for the effects
459 of medications that may influence clinical marker levels, affecting the clinical interpretation of
460 the identified markers. These limitations highlight important avenues for future research while
461 not diminishing the value of our population-level findings.

462 In conclusion, our work provides a comprehensive characterisation of multimorbidity
463 throughout the life course in a nationally representative population, revealing the complex and
464 dynamic nature of multimorbidity, shaped by disease interactions, distinct progression path-
465 ways, differential burden patterns, and social and biological factors. Collectively, these findings
466 highlight the need for adaptive and risk-stratified public health frameworks to inform targeted
467 prevention strategies, optimise healthcare resource allocation, and guide evidence-based poli-
468 cies to address the growing challenge of multimorbidity.




Figure 1: Study overview. **a**, Clinical diagnosis trajectories were extracted for participants over the life course, stratified by sex and age band. The example shown is for males. Trajectories were encoded as health state vectors representing the presence of specific conditions at each age band. Latent class analysis was applied within each stratum to identify multimorbidity clusters (e.g., $C_j^{i,M}$ denotes the j -th cluster within the i -th age band for males). **b**, To capture consistent multimorbidity patterns across age bands, hierarchical clustering was performed based on condition prevalence and exclusivity within the cluster. Condition prevalence was defined as the proportion of individuals within a cluster who had a given condition, whereas condition exclusivity was defined as the proportion of individuals with a specific condition in a given age band who belonged to that particular cluster. This yielded generic multimorbidity profiles (e.g., M1, M5, M9). **c**, Individual multimorbidity trajectories were reconstructed by mapping transitions across profiles over the life course. **d**, The burden associated with each profile was quantified using mortality, hospitalisation rate (mean annual hospitalisations per individual), and hospitalisation prevalence (proportion of individuals experiencing at least one hospitalisation). **e**, Descriptive analyses examined associations between multimorbidity and social factors, including socioeconomic deprivation, ethnicity, and geographic regions. **f**, An interpretable machine learning framework was developed to examine the association between multimorbidity and biological factors. Clinical marker trajectories over the life course were extracted and encoded into clinical marker vectors, stratified by sex and age band. A tree-based classifier XGBoost was trained to predict individual multimorbidity profiles from these vectors. A Shapley value-based explainer with novel reference-based adjustment was applied to identify clinically relevant markers for each profile.




Figure 2: Characteristics of the identified multimorbidity profiles for a, Males and b, Females. In each panel, the left part presents a heatmap of condition prevalence within each profile, with darker blue shades indicating higher prevalence (numerical results are provided in Supplementary Fig. S5). The middle part presents a bubble plot, where the size of circles corresponds to the prevalence for a profile across an age band (numerical results are provided in Supplementary Table S3–S4). The colour intensity reflects the mean number of conditions per individual, with darker red shades indicating a higher number of conditions. Profile labels are positioned between the two plots, and the right part lists the name of each profile, determined using the convention outlined in Supplementary Note S1.2. Conditions listed in the profile names are ordered by prevalence, and those with a mean number of conditions exceeding four are annotated as “Complex”. Condition abbreviations: anxiety (Anx), depression (Dep), serious mental illness (SMI), asthma (Ast), chronic obstructive pulmonary disease (COPD), diabetes (Diab), hypertension (Hyp), coronary heart disease (CHD), stroke or transient ischaemic attack (Stroke), atrial fibrillation (AF), heart failure (HF), peripheral arterial disease (PAD), chronic kidney disease (CKD), osteoporosis (Ost), rheumatoid arthritis (RA), cancer excluding non-melanoma skin cancers (Can).




Figure 3: Multimorbidity trajectories over the life course for a, Males and b, Females. The Sankey diagrams illustrate transitions of the 3.3 million individuals in the primary study cohort between multimorbidity profiles across different age bands. For each panel, the height of each bin is proportional to the number of individuals within the corresponding profile. Each coloured flow represents the transition of individuals from one profile to another, where the thickness of the flow is proportional to the number of individuals in the transition. Transitions from the same source profile are shown in the same colour. The common profiles across sexes are represented using the same colour, and profiles with similar condition compositions use similar hues. For clarity, transitions from individuals with no or single conditions into multimorbidity profiles are omitted, and the complete trajectories for the whole population are presented in Supplementary Fig. S6. An interactive demo of this figure is available for [males](#) and [females](#).




Figure 4: Multimorbidity burden over the life course. **a, b**, Mortality across multimorbidity profiles and age bands in males and females, respectively. Insets show a magnified view of the age bands below 65 years. **c, d**, Hospitalisation rate across multimorbidity profiles and age bands in males and females, respectively. For each panel, each line represents a multimorbidity profile, with values calculated within profile-specific cohorts for each age band. Mortality was defined as the proportion of individuals who died within each profile and age band. Hospitalisation rate was defined as the average number of hospitalisations per person-year within each profile for an age band. The healthy cohort is shown in grey for comparison. The colour coding follows the same scheme as in Fig. 3. More results on hospitalisation prevalence are provided in Supplementary Fig. S8.




Figure 5: Association between multimorbidity and social factors. **a, b**, Prevalence of multimorbidity profiles across IMD quintiles, from least deprived (IMD 1) to most deprived (IMD 5), for males and females, respectively. For each profile, the prevalence across IMD quintiles is shown. Profiles (i.e., sets of five bars) are sorted according to the IMD quintile with the highest prevalence within each profile. If multiple profiles share the same leading IMD quintile, they are further ordered by descending prevalence within that quintile. Vertical dashed lines separate profiles by the leading IMD quintile. **c, d**, Prevalence of multimorbidity profiles across ethnic groups (White, Black, and South Asian), for males and females, respectively. For each profile, the prevalence across ethnic groups is shown. Profiles (i.e., sets of three bars) are sorted according to the ethnic group with the highest prevalence within each profile. If multiple profiles share the same leading ethnic group, they are further ordered by descending prevalence within that group. Vertical dashed lines separate profiles by the leading ethnic group. **e, f**, Prevalence of multimorbidity profiles across nine regions of England, for males and females, respectively. For each profile, the prevalence across regions is shown. Profiles (i.e., sets of nine bars) are sorted according to the region with the highest prevalence within each profile. If multiple profiles share the same leading region, they are further ordered by descending prevalence within that region. Vertical dashed lines separate profiles by the leading region. A map of the regions is provided for reference. In all panels, each bar represents the prevalence of a profile within a specific group. For each bar, statistical significance was assessed using pairwise Z-tests with Bonferroni correction, comparing it to the other groups within the same profile. The largest (i.e., least significant) p-value among the comparisons is shown. Asterisks indicate significance levels (*p-value < 0.05, **p-value < 0.01, ***p-value < 0.001). Error bars for 95% confidence intervals are not shown, as the large sample size yields very narrow intervals with minimal impact on interpretability. IMD: Index of Multiple Deprivation.




Figure 6: Relevance of clinical markers across multimorbidity profiles for a, Males and b, Females. The heatmaps show the clinical relevance of each marker (columns) to each multimorbidity profile (rows), as determined by an interpretable machine learning framework (Methods). The hue (red/purple) indicates whether the marker value is abnormally high or low relative to a reference range, and the intensity (gradient) reflects the strength of its association. Markers are grouped by clinical system or physiological process (Supplementary Table S2). Beeswarm plots with SHAP values for each profile are provided in Supplementary Fig. S11–S12.

Table 1: Characteristics of each stratum in the primary study cohort

Characteristic	Sex	<18	18–24	25–34	35–44	45–54
Overall population ^a	Male	1,426,703 (43.04)	1,426,703 (43.04)	1,399,648 (43.26)	1,306,032 (43.78)	1,187,782 (44.10)
	Female	1,887,949 (56.96)	1,887,949 (56.96)	1,836,008 (56.74)	1,677,469 (56.22)	1,505,683 (55.90)
Multimorbid population ^b	Male	19758 (1.38)	116167 (8.14)	238997 (17.08)	321,591 (24.62)	443,941 (37.38)
	Female	34561 (1.83)	206475 (10.94)	390536 (21.27)	473,430 (28.22)	580,369 (38.55)
Mean conditions (overall) ^c	Male	0.12 (0.38)	0.28 (0.65)	0.50 (0.87)	0.74 (1.01)	1.14 (1.20)
	Female	0.13 (0.39)	0.34 (0.73)	0.60 (0.93)	0.82 (1.04)	1.15 (1.21)
Mean conditions (multimorbid) ^c	Male	2.09 (0.30)	2.19 (0.41)	2.23 (0.46)	2.30 (0.59)	2.48 (0.79)
	Female	2.11 (0.32)	2.19 (0.41)	2.23 (0.46)	2.30 (0.57)	2.48 (0.78)
Top 10 most prevalent conditions, (prevalence, %)	Male	Asthma, (9.26)	Asthma, (11.01)	Depression, (15.69)	Depression, (20.69)	Hypertension, (23.30)
		Anxiety, (1.35)	Depression, (7.38)	Anxiety, (14.73)	Anxiety, (18.49)	Depression, (23.10)
		Depression, (1.10)	Anxiety, (7.15)	Asthma, (13.03)	Asthma, (13.26)	Anxiety, (20.04)
		Cancer, (0.17)	SMI, (0.99)	Hypertension, (2.08)	Hypertension, (8.59)	Asthma, (13.70)
		SMI, (0.13)	Hypertension, (0.37)	SMI, (1.99)	Diabetes, (3.59)	Diabetes, (9.80)
		Hypertension, (0.10)	Cancer, (0.35)	Diabetes, (0.81)	SMI, (2.50)	CHD, (7.65)
		COPD, (0.08)	Diabetes, (0.12)	Cancer, (0.79)	CHD, (1.95)	Cancer, (2.96)
		Diabetes, (0.04)	COPD, (0.11)	CHD, (0.25)	Cancer, (1.45)	COPD, (2.58)
		Stroke, (0.03)	Stroke, (0.05)	COPD, (0.20)	COPD, (0.72)	SMI, (2.54)
		CHD, (0.02)	AF, (0.05)	AF, (0.17))	Stroke, (0.59)	Stroke, (2.14)
Top 10 most prevalent conditions, (prevalence, %)	Female	Asthma, (8.17)	Depression, (11.67)	Depression, (22.41)	Depression, (28.38)	Depression, (31.60)
		Depression, (2.07)	Asthma, (10.84)	Anxiety, (18.77)	Anxiety, (23.05)	Anxiety, (25.65)
		Anxiety, (1.92)	Anxiety, (9.85)	Asthma, (13.48)	Asthma, (14.22)	Hypertension, (18.73)
		Cancer, (0.14)	SMI, (0.56)	Hypertension, (1.85)	Hypertension, (6.57)	Asthma, (15.33)
		SMI, (0.10)	Hypertension, (0.41)	SMI, (1.31)	Diabetes, (2.22)	Diabetes, (5.74)
		Hypertension, (0.09)	Cancer, (0.29)	Cancer, (0.82)	Cancer, (2.08)	Cancer, (4.98)
		Diabetes, (0.04)	Diabetes, (0.13)	Diabetes, (0.62)	SMI, (1.85)	CHD, (2.33)
		RA, (0.04)	RA, (0.11)	RA, (0.34)	RA, (0.78)	SMI, (2.16)
		COPD, (0.04)	COPD, (0.06)	Stroke, (0.15)	COPD, (0.52)	COPD, (2.03)
		Stroke, (0.02)	Stroke, (0.05)	Osteoporosis, (0.12)	CHD, (0.48)	RA, (1.52)
Characteristic	Sex	55–64	65–74	75–84	≥85	
Overall population ^a	Male	1,025,303 (44.23)	804,781 (43.80)	520,119 (41.53)	212,069 (35.86)	
	Female	1,293,001 (55.77)	1,032,510 (56.20)	732,134 (58.47)	379,308 (64.14)	
Multimorbid population ^b	Male	569,714 (55.57%)	610,217 (75.82%)	480,029 (92.29%)	212,069 (100.00%)	
	Female	667,294 (51.61%)	708,136 (68.58%)	642,057 (87.70%)	379,308 (100.00%)	
Mean conditions (overall) ^c	Male	1.73 (1.40)	2.49 (1.55)	3.33 (1.63)	3.86 (1.57)	
	Female	1.61 (1.39)	2.26 (1.57)	3.14 (1.67)	3.85 (1.58)	
Mean conditions (multimorbid) ^c	Male	2.73 (1.02)	3.08 (1.28)	3.55 (1.51)	3.86 (1.57)	
	Female	2.72 (1.00)	3.03 (1.24)	3.48 (1.49)	3.85 (1.58)	
Top 10 most prevalent conditions, (prevalence, %)	Male	Hypertension, (42.48)	Hypertension, (59.57)	Hypertension, (68.77)	Hypertension, (69.88)	
		Depression, (22.26)	CHD, (27.58)	CHD, (35.56)	CKD, (46.06)	
		Anxiety, (19.22)	Diabetes, (25.57)	CKD, (30.51)	CHD, (39.08)	
		Diabetes, (18.14)	Depression, (18.62)	Diabetes, (28.62)	AF, (32.80)	
		CHD, (17.35)	Anxiety, (16.84)	Cancer, (27.16)	Cancer, (31.23)	
		Asthma, (14.31)	Cancer, (16.84)	AF, (22.82)	Stroke, (26.24)	
		Cancer, (7.43)	Asthma, (14.49)	Stroke, (19.43)	Diabetes, (25.61)	
		COPD, (6.64)	CKD, (13.17)	COPD, (16.58)	HF, (19.61)	
		Stroke, (5.66)	COPD, (12.24)	Depression, (15.36)	Dementia, (18.28)	
		AF, (4.69)	AF, (11.72)	Anxiety, (14.87)	COPD, (16.14)	
Top 10 most prevalent conditions, (prevalence, %)	Female	Hypertension, (35.67)	Hypertension, (55.22)	Hypertension, (70.72)	Hypertension, (75.88)	
		Depression, (30.80)	Depression, (27.24)	CKD, (30.33)	CKD, (47.63)	
		Anxiety, (25.63)	Anxiety, (23.94)	Depression, (24.39)	AF, (26.30)	
		Asthma, (16.45)	Asthma, (16.94)	Anxiety, (23.28)	CHD, (25.55)	
		Diabetes, (10.93)	Diabetes, (16.54)	Diabetes, (20.35)	Dementia, (25.02)	
		Cancer, (9.32)	Cancer, (14.62)	CHD, (20.26)	Osteoporosis, (24.53)	
		CHD, (6.47)	CHD, (13.05)	Cancer, (19.28)	Stroke, (23.83)	
		COPD, (4.95)	CKD, (12.91)	Osteoporosis, (18.43)	Anxiety, (22.41)	
		Osteoporosis, (4.40)	Osteoporosis, (10.26)	Asthma, (16.24)	Depression, (21.91)	
		CKD, (4.12)	COPD, (8.61)	AF, (15.37)	Cancer, (21.02)	

The rows labelled with “(overall)” report statistics for all individuals who ultimately developed multimorbidity by the end of the study. In contrast, the rows labelled with “(multimorbid)” report statistics for individuals who already had multimorbidity within the corresponding age band. Condition abbreviations: serious mental illness (SMI), chronic obstructive pulmonary disease (COPD), coronary heart disease (CHD), stroke or transient ischaemic attack (Stroke), atrial fibrillation (AF), heart failure (HF), chronic kidney disease (CKD), rheumatoid arthritis (RA), cancer excluding non-melanoma skin cancers (Cancer).

^a n (proportion within age band, %).

^b n (multimorbidity prevalence within sex and age band, %).

^c Mean number of conditions per individual (SD).

469 References

- 471 1. Skou, S. T. *et al.* Multimorbidity. *Nature Reviews Disease Primers* **8**, 48 (2022).
- 472 2. Russell, C. D., Lone, N. I. & Baillie, J. K. Comorbidities, multimorbidity and COVID-19. *Nature Medicine* **29**, 334–343 (2023).
- 474 3. Chowdhury, S. R., Das, D. C., Sunna, T. C., Beyene, J. & Hossain, A. Global and regional
475 prevalence of multimorbidity in the adult population in community settings: a systematic
476 review and meta-analysis. *eClinicalMedicine* **57** (2023).
- 477 4. Nguyen, H. *et al.* Prevalence of multimorbidity in community settings: a systematic review
478 and meta-analysis of observational studies. *Journal of Comorbidity* **9**, 2235042X19870934
479 (2019).
- 480 5. NHS England. The NHS belongs to the people: a call to action (2013). NHS England,
481 London.
- 482 6. Langenberg, C., Hingorani, A. D. & Whitty, C. J. Biological and functional multimorbidity—from
483 mechanisms to management. *Nature Medicine* **29**, 1649–1657 (2023).
- 484 7. Álvarez-Gálvez, J. *et al.* Social determinants of multimorbidity patterns: a systematic
485 review. *Frontiers in Public Health* **11**, 1081518 (2023).
- 486 8. MacMahon, S. *et al.* Multimorbidity: a priority for global health research. *The Academy
487 of Medical Sciences: London, UK* **127** (2018).
- 488 9. Gezsi, A. *et al.* Unique genetic and risk-factor profiles in clusters of major depressive
489 disorder-related multimorbidity trajectories. *Nature Communications* **15**, 7190 (2024).
- 490 10. Spencer, E., Ford, G., Chan, M., Perera, R. & Heneghan, C. Biomarkers in the prediction
491 of multimorbidity: scoping review. *medRxiv* 2020–11 (2020).
- 492 11. Kuan, V. *et al.* A chronological map of 308 physical and mental health conditions from
493 4 million individuals in the English national health service. *The Lancet Digital Health* **1**,
494 e63–e77 (2019).
- 495 12. Kuan, V. *et al.* Identifying and visualising multimorbidity and comorbidity patterns in pa-
496 tients in the English national health service: a population-based study. *The Lancet Digital
497 Health* **5**, e16–e27 (2023).
- 498 13. MacRae, C. *et al.* Age, sex, and socioeconomic differences in multimorbidity measured in
499 four ways: UK primary care cross-sectional analysis. *British Journal of General Practice*
500 **73**, e249–e256 (2023).
- 501 14. Sinnige, J. *et al.* The prevalence of disease clusters in older adults with multiple chronic
502 diseases—a systematic literature review. *PloS One* **8**, e79641 (2013).
- 503 15. Prados-Torres, A., Calderón-Larrañaga, A., Hancco-Saavedra, J., Poblador-Plou, B. &
504 van den Akker, M. Multimorbidity patterns: a systematic review. *Journal of Clinical
505 Epidemiology* **67**, 254–266 (2014).

506 16. Busija, L., Lim, K., Szoek, C., Sanders, K. M. & McCabe, M. P. Do replicable profiles of
507 multimorbidity exist? Systematic review and synthesis. *European Journal of Epidemiology*
508 **34**, 1025–1053 (2019).

509 17. McCutcheon, A. L. *Latent class analysis*. Quantitative Applications in the Social Sciences
510 (Sage Publications, Beverly Hills, CA, 1987).

511 18. Krauth, S. J. *et al.* Association of latent class analysis-derived multimorbidity clusters
512 with adverse health outcomes in patients with multiple long-term conditions: comparative
513 results across three UK cohorts. *eClinicalMedicine* **74** (2024).

514 19. Carmona-Pírez, J. *et al.* Identifying multimorbidity profiles associated with COVID-19
515 severity in chronic patients using network analysis in the precovid study. *Scientific Reports*
516 **12**, 2831 (2022).

517 20. Alvarez-Galvez, J., Ortega-Martin, E., Ramos-Fiol, B., Suarez-Lledo, V. & Carretero-
518 Bravo, J. Epidemiology, mortality, and health service use of local-level multimorbidity
519 patterns in South Spain. *Nature Communications* **14**, 7689 (2023).

520 21. Ioakeim-Skoufa, I. *et al.* Multimorbidity patterns and trajectories in young and middle-
521 aged adults: a large-scale population-based cohort study. *Frontiers in Public Health* **12**,
522 1349723 (2024).

523 22. Dervić, E. *et al.* Unraveling cradle-to-grave disease trajectories from multilayer comorbid-
524 ity networks. *npj Digital Medicine* **7**, 56 (2024).

525 23. Siggaard, T. *et al.* Disease trajectory browser for exploring temporal, population-wide
526 disease progression patterns in 7.2 million Danish patients. *Nature Communications* **11**,
527 4952 (2020).

528 24. Vetrano, D. L. *et al.* Twelve-year clinical trajectories of multimorbidity in a population of
529 older adults. *Nature Communications* **11**, 3223 (2020).

530 25. Haug, N. *et al.* High-risk multimorbidity patterns on the road to cardiovascular mortality.
531 *BMC Medicine* **18**, 1–12 (2020).

532 26. Cezard, G., McHale, C. T., Sullivan, F., Bowles, J. K. F. & Keenan, K. Studying trajectories
533 of multimorbidity: a systematic scoping review of longitudinal approaches and evidence.
534 *BMJ Open* **11**, e048485 (2021).

535 27. Cohen, N. M. *et al.* Longitudinal machine learning uncouples healthy aging factors from
536 chronic disease risks. *Nature Aging* **4**, 129–144 (2024).

537 28. Head, A., Birkett, M., Fleming, K., Kypridemos, C. & O’Flaherty, M. Socioeconomic in-
538 equalities in accumulation of multimorbidity in England from 2019 to 2049: a microsimu-
539 lation projection study. *The Lancet Public Health* **9**, e231–e239 (2024).

540 29. Barnett, K. *et al.* Epidemiology of multimorbidity and implications for health care, re-
541 search, and medical education: a cross-sectional study. *The Lancet* **380**, 37–43 (2012).

542 30. McKee, M. *et al.* The changing health needs of the UK population. *The Lancet* **397**,
543 1979–1991 (2021).

544 31. Kivimäki, M. *et al.* Overweight, obesity, and risk of cardiometabolic multimorbidity:
545 pooled analysis of individual-level data for 120 813 adults from 16 cohort studies from the
546 USA and Europe. *The Lancet Public Health* **2**, e277–e285 (2017).

547 32. Ferreira, G. D. *et al.* Physiological markers and multimorbidity: a systematic review.
548 *Journal of Comorbidity* **8**, 2235042X18806986 (2018).

549 33. Jørgensen, I. F., Haue, A. D., Placido, D., Hjaltelin, J. X. & Brunak, S. Disease trajectories
550 from healthcare data: methodologies, key results, and future perspectives. *Annual Review
551 of Biomedical Data Science* **7**, 251–276 (2024).

552 34. Wolf, A. *et al.* Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum.
553 *International Journal of Epidemiology* **48**, 1740–1740g (2019).

554 35. Head, A. *et al.* Inequalities in incident and prevalent multimorbidity in England, 2004–19:
555 a population-based, descriptive study. *The Lancet Healthy Longevity* **2**, e489–e497 (2021).

556 36. Gregg, E. W. *et al.* The burden of diabetes-associated multiple long-term conditions on
557 years of life spent and lost. *Nature Medicine* **30**, 2830–2837 (2024).

558 37. Ho, I. S. *et al.* Measuring multimorbidity in research: Delphi consensus study. *BMJ
559 Medicine* **1**, e000247 (2022).

560 38. MacRae, C. *et al.* The impact of varying the number and selection of conditions on es-
561 timated multimorbidity prevalence: a cross-sectional study using a large, primary care
562 population dataset. *PLoS Medicine* **20**, e1004208 (2023).

563 39. Diederichs, C., Berger, K. & Bartels, D. B. The measurement of multiple chronic dis-
564 eases—a systematic review on existing multimorbidity indices. *Journals of Gerontology
565 Series A: Biomedical Sciences and Medical Sciences* **66**, 301–311 (2011).

566 40. Salive, M. E. Multimorbidity in older adults. *Epidemiologic Reviews* **35**, 75–83 (2013).

567 41. Office for National Statistics. Death (2024). Accessed: 14 March 2025.

568 42. NHS Digital. Hospital episode statistics (2024). Accessed: 14 March 2025.

569 43. Chen, T. & Guestrin, C. XGBoost: a scalable tree boosting system. In *Proceedings of the
570 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining*,
571 785–794 (2016).

572 44. Covert, I., Lundberg, S. M. & Lee, S.-I. Understanding global feature contributions with
573 additive importance measures. *Advances in Neural Information Processing Systems* **33**,
574 17212–17223 (2020).

575 45. Lundberg, S. M. *et al.* From local explanations to global understanding with explainable
576 ai for trees. *Nature Machine Intelligence* **2**, 56–67 (2020).

577 46. Office for National Statistics. Ethnic group, Census 2021 estimates for England and Wales
578 (2022). Accessed: 11 March 2025.

579 47. Office for National Statistics. Regional economic activity by gross domestic product, UK:
580 1998 to 2020 (2024). Accessed: 11 March 2025.

581 48. Jani, B. D. *et al.* Relationship between multimorbidity, demographic factors and mortality:
582 findings from the UK Biobank cohort. *BMC Medicine* **17**, 1–13 (2019).

583 49. Agbonlahor, O. *et al.* Racial/ethnic discrimination and cardiometabolic diseases: a sys-
584 tematic review. *Journal of Racial and Ethnic Health Disparities* **11**, 783–807 (2024).

585 50. Booth, H. P., Prevost, A. T. & Gulliford, M. C. Impact of body mass index on prevalence
586 of multimorbidity in primary care: cohort study. *Family Practice* **31**, 38–43 (2014).

587 51. Sunyecz, J. A. The use of calcium and vitamin d in the management of osteoporosis.
588 *Therapeutics and Clinical Risk Management* **4**, 827–836 (2008).

589 52. Triposkiadis, F. *et al.* Aortic stiffness: a major risk factor for multimorbidity in the elderly.
590 *Journal of Clinical Medicine* **12**, 2321 (2023).

591 53. NHS England. Quality and outcomes framework guidance for 2024-25 (2024).

592 54. Morin, S. *et al.* StepMix: a python package for pseudo-likelihood estimation of generalized
593 mixture models with external variables. *arXiv preprint arXiv:2304.03853* (2023).

594 55. Virtanen, P. *et al.* Scipy 1.0: fundamental algorithms for scientific computing in python.
595 *Nature Methods* **17**, 261–272 (2020).

596 Methods

597 **Study population.** This work was conducted as part of CoMPuTE project (Complex Multiple
598 Long Term Conditions—Phenotypes, Trends, and Endpoints). We conducted a longitudinal co-
599 hort study using anonymised EHRs from CPRD³⁴, which received ethical approval (CPRD ref-
600 erence: 22_001771). Our cohort consisted of 6,671,245 individuals, including 3,314,652 who
601 developed multimorbidity (≥ 2 of 18 selected chronic conditions), 1,226,245 who remained
602 condition-free, and 2,130,348 with a single condition at the end of study. Participants were
603 followed from birth until the first occurrence of death or study exit no later than 31 December
604 2019. Study exit was defined as the earliest transfer out or the last practice download date.

605 **Chronic conditions.** We studied 18 chronic conditions selected based on prevalence and clin-
606 ical significance across major disease categories: mental health (anxiety, depression, serious
607 mental illnesses), respiratory (asthma, chronic obstructive pulmonary disease), metabolic (di-
608 abetes), cardiovascular (hypertension, coronary heart disease, stroke or transient ischaemic
609 attack, atrial fibrillation, heart failure, peripheral arterial disease), renal (chronic kidney dis-
610 ease), neurological (dementia, Parkinson's disease), musculoskeletal (osteoporosis, rheumatoid
611 arthritis), and oncological (cancers excluding non-melanoma skin cancers). Of these, 16 condi-
612 tions were selected from the QOF indicators, with anxiety and Parkinson's disease additionally
613 included due to their increasing prevalence and clinical relevance with age. SNOMED CT code
614 lists (<https://github.com/ndpchs-cprd/CPRD-22-001771-CoMPuTe/tree/main/Codelists>) were
615 used to ensure a consistent identification of conditions. The first recorded diagnosis of each
616 condition was assumed to reflect its presence thereafter. The selected conditions collectively
617 represent the majority of the multimorbidity impact, enabling examination of both physical-
618 mental health interactions and cross-system disease clustering patterns.

619 **Other measures and variables.** We included CPRD data on sex, date of birth, dates of di-
620 agnosis for each condition, IMD quintiles (as a measure of socioeconomic deprivation), eth-
621 icticity, and geographic region based on the location of the registered general practitioner. The
622 characteristics of the primary study cohort by social factors are summarised in Supplemen-
623 tary Table S1. Hospitalisation data were obtained through linkage with HES⁴², and mortality
624 data were linked from ONS⁴¹. In addition, we retrieved 45 conventional clinical markers from
625 CPRD records (Supplementary Table S2).

626 **Multimorbidity profile identification.** For each individual, we map the diagnosis of each
627 condition to nine age bands spanning the life course (from <18 to ≥ 85 years), creating 18-
628 dimensional binary health state vectors indicating which specific conditions had been diag-

629 nosed by the end of each age band. Within each age-sex stratum, we applied LCA¹⁷ to in-
630 dividuals with multimorbidity (≥ 2 conditions) to identify distinct clusters. Following previ-
631 ous studies^{7,18}, the optimal number of clusters was determined on the basis of model pars-
632 imony using the Bayesian information criterion (BIC), Akaike information criterion (AIC) and
633 consistent AIC (cAIC), which balance goodness of fit against model complexity to minimise
634 overfitting. Final selection further incorporated clinical relevance and interpretability, as es-
635 tablished through successive rounds of expert-panel review and consensus meetings within the
636 CoMPuTE consortium. For each identified cluster, we computed two key metrics: condition
637 prevalence, defined as the proportion of individuals within a cluster having each condition; and
638 condition exclusivity, defined as the proportion of individuals with a specific condition in a
639 given age band who belonged to that particular cluster (Supplementary Fig. S2–S3). Subse-
640 quently we applied agglomerative hierarchical clustering using Ward’s method to the vectors
641 of condition prevalence and exclusivity, thereby quantifying cluster similarity across age bands
642 (Supplementary Fig. S4). Clusters within each sex group were merged based on thresholds
643 informed by clinical interpretability and hierarchical clustering results (Supplementary Note
644 S1.1), thus forming multimorbidity profiles. Each multimorbidity profile was characterised by
645 its distinct composition of chronic conditions (Supplementary Fig. S5) and named according
646 to a convention detailed in Supplementary Note S1.2. This approach ensured accurate identi-
647 fication of sex- and age-specific profiles while capturing multimorbidity patterns consistently
648 across different strata. LCA was implemented using the StepMix package⁵⁴, and hierarchical
649 clustering was performed using the SciPy package⁵⁵ in Python v3.8.

650 **Multimorbidity trajectory reconstruction.** Using the multimorbidity profiles identified for
651 each individual across the age bands, we identified the longitudinal trajectories of multimor-
652 bidity. We also identified states in which individuals were free of all 18 chronic conditions
653 (denoted “H”), had a single condition (“S”), had died (“D”), or had exited the study (“E”).

654 **Multimorbidity burden assessment.** We assessed the burden of multimorbidity using three
655 metrics: mortality, hospitalisation rate, and hospitalisation prevalence. Mortality for each mul-
656 timorbidity profile was calculated within each age band as the proportion of individuals who
657 died while in that profile relative to the total number of individuals who experienced the profile
658 in that age band. The hospitalisation rate was defined as the mean number of hospitalisations
659 per year among individuals within a specific profile and age band. The prevalence of hospital-
660 isation represented the proportion of individuals hospitalised at least once during the age band
661 relative to the total number of people who experienced the profile in that age band.

662 **Statistical analysis with social factors.** We analysed the association between the multimorbid-
663 ity profiles and key social factors: socioeconomic deprivation, ethnicity, and geographic region.
664 For each profile, we calculated its prevalence across subgroups within each social factor and
665 performed statistical significance tests using pairwise Z-tests with Bonferroni correction. For
666 each subgroup-profile combination, we compared prevalence with all other subgroups within
667 the same profile and reported the least significant p-value from these comparisons.

668 **Interpretable machine learning framework with biological factors.** Although clinical mark-
669 ers are well-established indicators for individual conditions, their role in multimorbidity re-
670 mains poorly characterised^{6,10}. The synergistic effects of coexisting conditions can substan-
671 tially alter clinical marker patterns, rendering condition-level associations insufficient for iden-
672 tifying profile-level markers. To address this, we developed an interpretable machine learning
673 framework using XGBoost⁴³ combined with a novel reference-adjusted SHAP^{44,45} to quan-
674 tify the relevance of clinical markers to specific multimorbidity profiles in a data-driven man-
675 ner. This framework offers several advantages: XGBoost inherently handles missing values
676 and maintains scale invariance across heterogeneous marker distributions, while the reference-
677 adjusted SHAP quantifies individual marker contributions relative to clinical reference ranges,
678 thereby improving clinical interpretability.

679 For each individual in each age band, we extracted the most recent measurement of the 45
680 clinical markers, aligning with the latest diagnosis information used for profile identification.
681 This resulted in clinical marker vectors that represented individuals' biological states in spe-
682 cific age bands. Missing marker values were explicitly indicated in vectors, and each clinical
683 marker vector was labelled according to the individual's multimorbidity profile in the corre-
684 sponding age band. We then sampled 10,000 clinical marker vectors per profile for each sex,
685 creating two datasets comprising 210,000 male and 180,000 female samples. These datasets
686 were divided into training subsets (80%) and testing subsets (20%). An XGBoost classifier
687 was trained to predict multimorbidity profiles based on clinical markers, formulated as a multi-
688 class classification task. Owing to XGBoost's inherent ability to handle missing values and
689 scale invariance, we did not perform additional preprocessing or normalisation. The key hyper-
690 parameters included a learning rate of 0.1, a maximum tree depth of 12, and 500 boosting iter-
691 ations. The performance metrics of the model demonstrated robust discrimination, with males
692 achieving an area under the receiver operating characteristic curve (AUROC) of 0.894, area
693 under the precision-recall curve (AUPRC) of 0.384, and top-k accuracy of 0.383 (k=1), 0.677
694 (k=3), and 0.814 (k=5). Female models showed comparable performance (AUROC=0.891,
695 AUPRC=0.413) with top-1 (0.402), top-3 (0.703) and top-5 (0.841) accuracy. In practice, a

696 top-k prediction of the most probable profiles could enable clinicians to prioritise preventive
697 and monitoring strategies tailored to the likeliest progression pathways. To improve clinical
698 interpretability, we implemented a reference-adjusted SHAP methodology. Traditional SHAP
699 analysis can highlight markers that are valuable for classification but clinically irrelevant, such
700 as markers of the normal range incorrectly identified as important indicators. Our approach
701 focused specifically on markers whose abnormal values (outside the clinically defined refer-
702 ence ranges) positively contributed to the correct identification of multimorbidity profiles. We
703 defined clinical relevance as the mean SHAP value among samples with positive SHAP values
704 and clinical marker values beyond their normal reference ranges (Fig. S11–S12). This refined
705 analysis identified clinical markers that are associated with multimorbidity profiles, potentially
706 serving as early clinical indicators for these profiles. We conducted these analyses using the
707 xgboost package⁴³ and the SHAP package⁴⁵ in Python v3.8.

708 **Ethical approval.** The CPRD database is approved by the East Midlands–Derby Research
709 Ethics Committee, reference 05/MRE04/87 for public health research according to approved
710 research protocols, and the research protocol for this study received specific approval from the
711 CPRD’s Research Data Governance (reference 22 00177).

712 **Data availability.** Data supporting the findings of this study are available in the article and its
713 Supplementary information. The data underlying this article is provided by the UK CPRD elec-
714 tronic health record database, which is only accessible to researchers with protocols approved
715 by CPRD’s Research Data Governance.

716 **Code availability.** The code used for this study is available at <https://github.com/liuyuaa/CoMPuTE-Multimorbidity-in-England>.

718 **Acknowledgements.** This project is funded by the NIHR Programme Grants for Applied Re-
719 search Programme (NIHR204406). The views expressed are those of the author(s) and not nec-
720 cessarily those of the NIHR or the Department of Health and Social Care. This study is based in
721 part on data from the Clinical Practice Research Datalink obtained under licence from the UK
722 Medicines and Healthcare products Regulatory Agency. The data is provided by patients and
723 collected by the NHS as part of their care and support. The interpretation and conclusions con-
724 tained in this study are those of the authors alone. T. Zhu was supported by the Royal Academy
725 of Engineering under the Research Fellowship scheme. We thank X. Li for clinical advice and
726 Y. Jiang for visualisation advice.

727 **Authors contributions.** Y.L. and T.Z. conceived and designed the study with advice from all
728 authors. C.B., C. W. D. and S.S. performed data acquisition and curation. Y.L. developed

729 the analytical framework, implemented machine learning methods, conducted all analyses, and
730 drafted the manuscript. Y.L., C.B., C.W.D., C.P., D.G., R.P. and T.Z. led the initial interpre-
731 tation of results. All authors discussed the findings, contributed to manuscript revisions, and
732 approved the final version.

733 **Competing interests.** The authors declare no competing interests.

734 **Consortia.** CoMPuTE Consortium:

735 Sami Adnan², Henrique Aguiar¹, Anica Alvarez Nishio², Amitava Banerjee⁴, Clare Bankhead²,
736 Derrick Bennett⁵, Kamaldeep Bhui^{2,6}, Benjamin Cairns⁷, Mei Chan⁵, Andrew Clegg⁸, Caro-
737 line Cupit², Ashkan Dashtban⁴, Cynthia Wright Drakesmith², Margaret Glogowska², David
738 Gonzalez³, Mackenzie Graham⁵, Odessa Hamilton², Ishbel Henderson², Carl Heneghan², Joanna
739 Lach², Mary Logan², Sapfo Lignou⁵, Yu Liu¹, Micheal McKenna², Brian Nicholson², Igho
740 Onakpoya², Rafael Perera-Salazar², Nicola Piddock², Catherine Pope², John Powell², Samuel
741 Relton⁸, Eve Rodgers⁶, Anna Seeley², Mark Sheehan⁵, James Sheppard², David Steinsaltz⁹,
742 Subhashisa Swain², Tazeen Tahsina², Paul Taylor⁴, Oliver Todd⁸, Apostolos Tsiachristas², An-
743 thony Webster⁹, Tingting Zhu¹

744 ¹Department of Engineering Science, University of Oxford, Oxford, UK.

745 ²Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.

746 ³Discipline of General Practice, University of Adelaide, Adelaide, Australia

747 ⁴Institute of Health Informatics, University College London, London, UK.

748 ⁵Nuffield Department of Population Health, University of Oxford, Oxford, UK.

749 ⁶Department of Psychiatry, University of Oxford, Oxford, UK.

750 ⁷Our Future Health, London, UK.

751 ⁸School of Medicine, University of Leeds, Leeds, UK.

752 ⁹Department of Statistics, University of Oxford, Oxford, UK.